{"disease":{"id":"hutchinson-gilford-syndrome","name":"Hutchinson-Gilford syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lonafarnib","indication_name":"Hutchinson-Gilford syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zokinvy","generic_name":"LONAFARNIB","company_name":"Sentynl Theraps Inc","drug_phase":"marketed","molecular_target":"farnesyltransferase","drug_class":"Farnesyltransferase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Lonafarnib prevents farnesylation of progerin and similar proteins by inhibiting farnesyltransferase."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04512963","title":"Phase I Study of Progerinin in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"PRG Science & Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03871972","title":"Umbilical Cord Blood Transfusion in Progeria Syndrome","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Bundang CHA Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}